Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

which are developing a drug that preferentially targets just one of the orexin receptors thought to be more relevant to maintaining wakefulness. Their selective orexin 2 receptor antagonist ...

or orexin receptor 2 (OX2R). These receptors regulate sleep and wakefulness, stress responses, and appetite. Drugs like Belsomra block the activity of these neurotransmitters by attaching to the ...

Greg Smith to develop computational models to predict drug-induced changes in performance in attention-demanding tasks ... 2010). We reported that blockade of orexin-1 receptors with SB-334867, either ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...

For instance, daridorexant, a novel orexin receptor antagonist, has shown promise in improving sleep outcomes and daytime functioning in individuals with insomnia disorder. Clinical trials ...